ATE399776T1 - Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors - Google Patents

Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors

Info

Publication number
ATE399776T1
ATE399776T1 AT04749151T AT04749151T ATE399776T1 AT E399776 T1 ATE399776 T1 AT E399776T1 AT 04749151 T AT04749151 T AT 04749151T AT 04749151 T AT04749151 T AT 04749151T AT E399776 T1 ATE399776 T1 AT E399776T1
Authority
AT
Austria
Prior art keywords
pyrrole
modulators
liver
receptor
dithione
Prior art date
Application number
AT04749151T
Other languages
English (en)
Inventor
Patrik Holm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE399776T1 publication Critical patent/ATE399776T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04749151T 2003-07-11 2004-07-08 Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors ATE399776T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316237.7A GB0316237D0 (en) 2003-07-11 2003-07-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE399776T1 true ATE399776T1 (de) 2008-07-15

Family

ID=27741986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749151T ATE399776T1 (de) 2003-07-11 2004-07-08 Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors

Country Status (26)

Country Link
US (1) US20060189663A1 (de)
EP (1) EP1646625B1 (de)
JP (1) JP2007521313A (de)
KR (1) KR20060034284A (de)
CN (1) CN100478340C (de)
AR (1) AR045720A1 (de)
AT (1) ATE399776T1 (de)
AU (1) AU2004256000B2 (de)
BR (1) BRPI0412479A (de)
CA (1) CA2532068A1 (de)
CO (1) CO5640134A2 (de)
DE (1) DE602004014772D1 (de)
ES (1) ES2308205T3 (de)
GB (1) GB0316237D0 (de)
HK (1) HK1088318A1 (de)
IL (1) IL172759A0 (de)
IS (1) IS8291A (de)
MX (1) MXPA06000447A (de)
NO (1) NO20060080L (de)
RU (1) RU2006102129A (de)
SA (1) SA04250203B1 (de)
TW (1) TW200507836A (de)
UA (1) UA82108C2 (de)
UY (1) UY28407A1 (de)
WO (1) WO2005005416A1 (de)
ZA (1) ZA200600229B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2592771A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
JP4936476B2 (ja) * 2005-06-28 2012-05-23 第一三共株式会社 Ｌｘｒリガンドの試験方法
JP5349306B2 (ja) 2006-08-21 2013-11-20 ジェネンテック， インコーポレイテッド アザベンゾチオフェニル化合物および使用方法
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008046014A1 (en) * 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
US20100143270A1 (en) * 2007-02-21 2010-06-10 University Of Louisville Research Foubdation Therapeutic cotinine compositions
DK2868315T3 (en) 2007-12-04 2017-09-04 Biogen Chesapeake Llc IMPROVED FORMULATIONS AND PROCEDURES FOR FREEZING DRYING AND THEREOF, LYOFILATES PREPARED
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
WO2010003025A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
CN102137843A (zh) 2008-07-01 2011-07-27 健泰科生物技术公司 作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法
BR112013005425A2 (pt) 2010-09-07 2018-05-02 Snu R&Db Foundation compostos sesterterpenos e suas utilizações
EP3091970B1 (de) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr-agonisten und verwendungen davon
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
KR200492570Y1 (ko) 2018-12-04 2020-11-05 박규환 조립식 계단장치를 위한 발판
JP2023509845A (ja) 2019-12-13 2023-03-10 インスピルナ，インコーポレーテッド 金属塩及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
EP1212065A4 (de) * 1999-07-08 2004-02-11 Tularik Inc Zusammenstellungen und methoden zur erhöhung des hdl cholesterolspiegels

Also Published As

Publication number Publication date
ZA200600229B (en) 2007-04-25
AU2004256000B2 (en) 2007-07-26
SA04250203B1 (ar) 2008-02-25
AR045720A1 (es) 2005-11-09
BRPI0412479A (pt) 2006-09-19
EP1646625B1 (de) 2008-07-02
ES2308205T3 (es) 2008-12-01
US20060189663A1 (en) 2006-08-24
CO5640134A2 (es) 2006-05-31
CA2532068A1 (en) 2005-01-20
KR20060034284A (ko) 2006-04-21
HK1088318A1 (en) 2006-11-03
CN100478340C (zh) 2009-04-15
WO2005005416A1 (en) 2005-01-20
IL172759A0 (en) 2006-04-10
GB0316237D0 (en) 2003-08-13
MXPA06000447A (es) 2006-04-07
IS8291A (is) 2006-02-09
UA82108C2 (uk) 2008-03-11
JP2007521313A (ja) 2007-08-02
AU2004256000A1 (en) 2005-01-20
TW200507836A (en) 2005-03-01
UY28407A1 (es) 2005-02-28
DE602004014772D1 (de) 2008-08-14
NO20060080L (no) 2006-02-08
RU2006102129A (ru) 2006-08-27
EP1646625A1 (de) 2006-04-19
CN1820003A (zh) 2006-08-16

Similar Documents

Publication Publication Date Title
HK1088318A1 (en) Pyrrole-2, 5-dithione derivatives as liver x receptor modulators
IL172760A0 (en) Pyrrole-2,5-dithione derivatives as liver x receptor modulators
ATE440085T1 (de) 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
ATE451364T1 (de) Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
MA28391B1 (fr) Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
PT1444215E (pt) Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE420881T1 (de) Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE387202T1 (de) Pyrrolidinderivate als histaminrezeptor-liganden
DE60305903D1 (de) Tropanderivative als ccr5-modulatoren
ZA200609234B (en) Substituted azeplne derivatives as serotonin receptor modulators
DE602005023600D1 (de) Substituierte 1-phenyl-1,5-dihydro-pyridoä3,2-büindol-2-on-derivate verwendbar als pharmazeutische antiinfektiva
AU2003256922A8 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
ZA200804349B (en) 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as H3 modulators
BRPI0509256A (pt) derivados de pirrolidina-3,4-dicarboxamida
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
ATE398620T1 (de) Spirokondensierte indolinderivate als pestizide
DE602004009583D1 (de) Piperidin- oder 8-azabicycloä3.2.1üoct-3-ylderivate, die sich als modulatoren der chemokinrezeptoraktivität eignen
DE602004006424D1 (de) Piperidinderivate als ccr5-rezeptormodulatoren
ZA200606563B (en) 3-Substituted 1,5-diphenylpyrazole derivatives useful as CB1 Modulators
IL165408A0 (en) Novel substituted indoles

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties